Patent · US Active

Compositions and methods for inhibiting expression of the ALAS1 gene

US10400239B2 · kind B2 · utility

1Cited by

3References

51Claims

0Family size

Assignees

Alnylam Pharmaceuticals, Inc. · US
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · US

Inventors

Brian Bettencourt · Groton, US
Kevin Fitzgerald · Brookline, US
William Querbes · Boston, US
Robert J. Desnick · New York, US
Makiko Yasuda · New York, US

Key dates

Filing date	Mar 13, 2017
Grant date	Sep 3, 2019
Priority date	—
Expiry date	Mar 13, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y203/01037
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.